USP and Public Policy
Left
Refine Your Search
USP comments submitted to FDA for Docket No. FDA-2019-N-1845: Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain. Comments…
Learn More
USP Comments submitted to FDA on Continuous Manufacturing for Docket No. FDA-2017-N-2697 for “Submission of Proposed Recommendations for Industry on Developing Continuous Manufacturing of Solid…
Learn More
USP Comments to FDA Public Meeting: “The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” Regarding Generic Medicines. Comments were submitted 7-18-2017.
Learn More
Submitted August 18, 2023 to Senators Sanders and Cassidy and Representatives McMorris-Rodgers and Pallone regarding the Request for Information Regarding the Food and Drug Administration Regulation…
Learn More
USP appreciates the opportunity to provide comments for the National Conference on Weights and Measures’ (NCWM) consideration on proposed commercial measurement standards for cannabis and cannabis-…
Learn More
Promoting geographic diversification of the manufacturing base for U.S. drug products can help reduce supply chain vulnerabilities. Published December 2023.
Learn More
USP supports comprehensive policies and programs to address AMR, including building capabilities among global stakeholders to reduce the proliferation of poor-quality medicines and advocating and…
Learn More
USP Global Public Policy Position published 2024
Learn More
The United States Pharmacopeia (USP) is pleased to support the “Mapping America’s Pharmaceutical Supply Act” (H.R. 6992), or the MAPS Act.
Learn More
Recently, media reports have highlighted the results of drug quality testing from some contract laboratories that are analyzing the quality attributes of human drug products using testing methods…
Learn More